Publication for HOXA1 and HOXA9

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	HOXA1	homeobox A1	3198			[link]
hsa	HOXA9	homeobox A9	3205

Pubmed ID	Priority	Text
30952900	0.98	HOXA9 HD was sufficient to rescue the effect of the HX mutation in HOXA1.
	0.97	HOXA9 HD for complex formation with TALE cofactors was further confirmed by generating a chimeric protein consisting of full length HOXA9 containing the HOXA1 HD, with or without the HX mutation (constructs A9HDA1 and A9HDA1HX in Fig. 1C).
	0.97	HOXA1, HOXA9 and HOXA7).
	0.95	HOXA1 chimeric protein, since their mutation strongly affected the rescue activity of the HOXA9 HD (Supplementary Fig. S3).
	0.91	HOXA9 and HOXA1 protein fragments are in red or blue, respectively.
	0.90	HOXA1-HOXA9 proteins confirmed that the HOXA9 HD was necessary and sufficient (in the context of HOXA1) for the interaction with PBX1 in HEK cells (Figs 2G-G',H-H' and S1).
	0.88	HOXA1 HX mutation with the HOXA9 HD was not fully compromised by the additional mutation of the D29 and M56 residues in vitro.
	0.87	HOXA9 HD was found to be sufficient to interact with PBX1 and MEIS1, not only in the context of HOXA9, but also in the context of HX-mutated HOXA1.
28614722	0.97	HoxA1, HoxA5 and HoxA9, each in complex with the cofactor PBX1, which was purified together with the HM domain of MEIS1.
	0.97	HoxA1 whereas for HoxA9 DeltaDeltaG[C9 5mC9]/RT is close to zero (Figure 5B).
	0.97	HoxA1 and HoxA9.
	0.96	HoxA1, HoxA5 or HoxA9 (green, orange, red).
	0.95	HoxA1 prefers a T over a C, whereas HoxA9 has equal preference.
	0.93	HoxA1 and HoxA9, which show distinct differences in methylation preference at position 9: Pbx-HoxA1 strongly prefers T over C (DeltaDeltaG[C T]/RT -2.0), while Pbx-HoxA9 shows no such preference (Figure 5B).
	0.89	HoxA1 having high, HoxA5 medium, and HoxA9 almost no methylation sensitivity; position 5/6 shows the opposite trend.
	0.77	HoxA1, TA for central (Class II) factor HoxA5, and TT for posterior (Class III) factor HoxA9 (Figure 4D).
	0.73	HoxA1 and HoxA9 is most likely driven by the methyl read-out.
	0.71	HoxA1, HoxA5 and HoxA9, respectively.
27980680	0.97	HOXA1, HOXA3, HOXA5 and HOXA9 genes but not of HOXA13 or GLCCI1 (Fig. S2b), consistent with previous results (Fig. 3a).
	0.91	HOXA1, HOXA3, HOXA5 and HOXA9 were significantly upregulated in Nup188- and Nup205-depleted cells (Fig. 3b, c).
	0.88	HOXA1, HOXA3, HOXA5 and HOXA9) were strikingly upregulated (fold change >twofold) upon Nup93 Kd (Fig. 3a).
28783698	0.97	HOXA1 and HOXA9 in human M(IFN-gamma).
	0.96	HOXA1 and HOXA9 upon siRNA-mediated knockdown of SP140, relative to HPRT as determined by qPCR.
	0.93	HOXA1 and low HOXA9 (Fig. 3F, inset).
19782034	0.97	HOXA1 construct, 35% in HOXA9, and 15% in PIM1, and 17% in TP53I11 constructs compared to co-transfection with pcDNA3.1 control plasmid (Fig. 5C - F).
25912306	0.96	HOXA9 and HOXA1.
	0.72	HOXA9 (>80%) and HOXA1 (>60%), whereas siHOTTIP decreased expression of HOXB7 by <25% (Figure 6C).
24312487	0.96	HOXA1) are expressed prior to the 5' genes (e.g., HOXA9) within a given clusters.
26485654	0.96	HOXA1, HOXA2, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10 and HOXA11 from HOXA-cluster.
28180285	0.96	HOXA1 to A5:were dramatically induced upon RA addition while distal HOXA9 to A13 remained silent (Figure 1C).
31375530	0.96	HoxA1 (as control) or GFP-2xGLFG-HoxA9 were stained for PolyA+ RNA FISH and immunostained with anti-NXF1.
26848759	0.95	HOXA1, A2 and A5 genes were transcriptionally activated, whereas HOXA9 and A10 transcript levels remained unchanged (Fig 2A).
	0.60	HOXA1 and A2 genes were transcriptionally induced (HOXA5 weakly), while HOXA9 and A10 transcript levels remained constant upon ATRA treatment in siControl transfected cells (Fig 2B).
25622821	0.95	HOXA9-13 is predominantly found in sites of the extremities, while HOXA1-2 expression has been confirmed in, for example, the hindbrain.
24649818	0.94	HOXA1, HOXA4, HOXA5, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13, HOXD3, HOXD4, HOXD9 and WT1) and other frequently studied genes, such as APC, RASSF1A, GSTP1, CDH13, CDKN1C, CDKN2A, KLK10, RUNX3 and S100A2 (see Table 4 of reference for the full list).
	0.93	HOXA1, HOXA4, HOXA5, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13, HOXD3, HOXD4, HOXD9, HPSE, HPP1, HSPB1, HSPRY2, KBTBD6, LAM-A3, LAM-B3, LAM-C3, KLK10, LRRC3B, MAL, MCAM, MDR1, MGMT, MTIG, NEP, NKX2-5, NOTCH1, NTRK2, PDLIM4, PITX2, PTGS2, PXMP4, RASSF1A, RARB, RARRES1, RIZ1, RRAD, RTVP1/GLIPR, RUNX3, SCGB3A1, SERPINB5, SFN, SFRP1, SLIT2, SNCG, SOCS1, S100A2, S100A6, THBS1, THRB, TIG1, TIMP3, TWIST1, VDR, WT1, ZNF185
24373511	0.94	HOXA1 and the 5' HOXA subcluster including HOXA7, HOXA9, HOXA10, HOXA11, and HOXA13 (Figure 8).
29137433	0.94	HOXA1, HOXA4, HOXA7, HOXA9, HOXB2, HOXB3, HOXB5-9, HOXC4, HOXC5, HOXC13, HOXD1, HOXD9, HOXD10, HOXD11, and HOXD13 (P < 0.001).
30992047	0.93	HOXA1, HOXA7, HOXA9, HOXA10, HOXB1, and HOXB7) in anencephaly, we evaluated 10 anencephaly cranial tissues and 10 matched normal fetus cranial samples by the NanoString technique.
	0.91	HOXA1, HOXA9, and HOXB1.
	0.87	HOXA1, HOXA7, HOXA9, HOXA10, HOXB1, and HOXB7 genes upon CUL4B knockdown cells (Additional file 1: Fig. S1c and S1d).
	0.74	HOXA1, HOXA7, HOXA9, HOXA10, HOXB1, and HOXB7 genes were upregulated in CUL4B-depleted NT2 cells (Additional file 1: Fig. S1b).
	0.73	HOXA1, HOXA10, HOXB1, and HOXB7, but had only weak effects on HOXA7 and HOXA9 (Additional file 1: Fig. S3c).
22569366	0.93	HOXA1, in the HOXA3 gene body, in several regions between HOXA4 and HOXA7 and in the HOXA9 locus.
26137584	0.93	HOXA1 gene transcription was slightly increased, while that one of HOXA7, HOXA9 and HOXA10 was slightly reduced in the presence of dnTASP1.
29117547	0.93	HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, and HOXA13) and various anti-sense non-coding RNAs such as HOTAIRM1 and HOTTIP.
24174538	0.92	HoxA1 to A7 represent the 3'-end genes, and 5'-end genes include HoxA9 to A13.
31426381	0.89	HOXA1, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 was upregulated in patients with leukemia (Table 1).
	0.55	HOXA9, and HOXA10 were significantly increased in human AML patients compared to those in normal samples (P < 0.05), whilst the expression levels of HOXA1, HOXA11, and HOXA13 were not significantly different (Figure 2).
22708672	0.83	HOXA9, HOXA2 and HOXA1 are highly conserved in all species.
31681594	0.83	HOXA1 (P = 0.0112), HOXA2 (P = 0.019), HOXA3 (P < 0.0001), HOXA4 (P = 0.0005), HOXA5 (P < 0.0001), HOXA6 (P < 0.0001), HOXA7 (P < 0.0001), HOXA9 (P = 0.0004), HOXA10 (P < 0.0001), HOXB2 (P = 0.0026), HOXB3 (P < 0.0001), HOXB4 (P < 0.0001), HOXB6 (P < 0.0001), MEIS1 (P = 0.0001), and PRDM16 (P = 0.0002) genes were all expressed at higher levels compared with high miR-340 expression group.
27382069	0.74	HOXA1 in activating the TNF/NF-kappaB pathway was assessed using the NF-kappaB reporter and HOXA1, HOXA2, HOXA9, HOXB9 and HOXD9 expression plasmids in the human mammary epithelial cell line MCF10A.
27156077	0.71	HOXA1, HOXA9), and the myc antagonist MNT.
23168266	0.66	HOXA1, and HOXA9, are also reported to be hypermethylated in breast cancer, suggesting that aberrant methylation and silencing of these gene sets may be as important to carcinogenesis as the aberrant silencing of tumor suppressors.
32104178	0.56	HOXA1, HOXB6, HOXA9, HOXA10, murine Hoxb6 and Meis1, and Xenopus XlHbox2, have also been reported to generate splice variants lacking homeodomains.
23848554	0.55	HOXA1, HOXA9, and HOXA3, miR-10a and miR-10b target HOXA3 and HOXD10, and miR-9 target CDX2.
23125370	0.53	Hox-A1 (HOXA1), Homeobox protein Hox-A9 (HOXA9) and Max-binding protein (MNT).